

Universal Vision Biotechnology Co., Ltd.

Notice of the 2025 Annual General Shareholders' Meeting

- I. The 2025 Annual General Shareholders' Meeting (the "Meeting") of Universal Vision Biotechnology Co., Ltd. (the "Company") will be convened at 9:00 a.m. on Monday, May 26, 2025 at 4F, No. 3-1, Yuanqu St., Nangang Dist., Taipei City 115, Taiwan. The shareholder check-in will begin at 8:30 a.m., and the Meeting will be supported by video conferencing. The agenda for the Meeting is as follows:
- A. Reporting matters
 - a. 2024 Business Report
 - b. 2024 Final Accounts Report reviewed by the Audit Committee
 - c. Report on the distribution status of 2024 employee compensation and director remuneration
 - d. Report on the distribution status of 2024 cash dividends
 - e. Report on the investment status in Mainland China
 - f. Report on the status of undertaking the endorsement and guarantee
 - g. Report on the Company's 2024 director remuneration
 - B. Acknowledgment matters
 - a. Acknowledgment of 2024 business report and financial statements
 - b. Acknowledgment of 2024 Statement of the Distribution of Earnings
 - C. Discussion matters :
 - a. Discussion to revise the Company's Articles of Incorporation
 - b. Discussion to revise the Company's Procedures for Acquisition or Disposal of Assets
 - c. Discussion to revise the Company's Procedures for Lending Funds to Other Parties
 - d. Discussion to revise the Company's Rules of Procedure for Shareholders Meetings
 - D. Extemporaneous motions
- II. The Board of Directors has approved the cash dividend from 2024's profits to be NT\$7.5 per share, and the cash dividend has been distributed on April 21, 2025.
- III. When items specified in Article 172 of the Company Act contain in the main content of the Meeting, apart from listing them in the notice to meeting, please visit the Market Observation Post System at <https://emops.twse.com.tw> and select "Electronic Books/Shareholders' meetings" for details.

IV. Pursuant to Article 165 of the Company Act, share transfer registration for the Company will be closed from March 28, 2025 to May 26, 2025.

V. In addition to making an announcement on the Market Observation Post System, the letter, annexed with a notice of attendance and a proxy statement, is delivered additionally. Please sign or seal in the "Notice of Attendance" while you want to attend the Meeting in person, and use it to register for attendance on the date of meeting. Shareholder may sign or seal in the "Proxy Statement" and fill in the name and address of the proxy in person to appoint a proxy to attend the Meeting on his or her behalf by executing a power of attorney. Please send out such written "Proxy Statement" to the Company's stock agency, Grand Fortune Securities Co., Ltd. and its Stock Agency Department, no later than five days prior to the meeting date, enabling the mailing of the sign-in card or the attendance card required for attendance.

VI. If there is public solicitation of proxy, the Company will publish relevant information on the website of Securities and Futures Institute no later than April 25, 2025. Please visit <https://free.sfi.org.tw> and go to "Proxy Solicitation Inquiry System", entering the Company's name/ticker for information.

VII. The Company may allow the shareholders to exercise voting rights by electronic means, from April 26, 2025 to May 23, 2025. Please log onto the "eVoting" website of Taiwan Depository and Clearing Corp. at <https://stockservices.tdcc.com.tw> and follow the instructions.

VIII. The tallying and verification institution of proxy statement for the Meeting is the Stock Agency Department of Grand Fortune Securities Co., Ltd.

IX. It is highly appreciated that you handle the matters accordingly.

Sincerely,

Board of Directors

Universal Vision Biotechnology Co., Ltd.